Clinical trials
Respiratory Syncytial Virus (RSV) clinical trials
Below are recruiting respiratory syncytial virus (rsv) clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07764237RecruitingPhase 1
mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Québec, QuebecAges 60 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06851806Recruiting
Palivizumab study for children at high risk of severe RSV
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
HyderabadAges Any age - NCT06754605RecruitingPhase 1/Phase 2
Testing a new RSV vaccine for safety and immune response
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Langfang, HebeiAges 18–120 - NCT06881056Recruiting
Aerosol interferon for RSV pneumonia in toddlers
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Chengdu, SichuanAges 1–3 - NCT07543380RecruitingPhase 3
RSV vaccine safety and immune response in high-risk adults
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Tsuchiura, IbarakiAges 18–59 - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT07717840RecruitingPhase 1/Phase 2
RSV vaccine study for adults 60 and older
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
Long Beach, CaliforniaAges 60 years+ - NCT06488300RecruitingPhase 2
Testing antiviral treatments for early RSV
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
VientianeAges 18–64 - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT07734649RecruitingPhase 1/Phase 2
RSV and HMPV vaccine study for adults 60 and older
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Gadsden, AlabamaAges 60 years+ - NCT07615192Recruiting
RSV Vaccination Experiences in Queensland Infants
This study asks parents in Queensland about their infant's RSV (respiratory syncytial virus) vaccination status and experiences. RSV is a common virus that can cause serious breathing problems in babies, and this research helps understand vaccination patterns.
Brisbane, QueenslandAges 18 years+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT05655182RecruitingPhase 1/Phase 2
RSV vaccine study for infants and toddlers who may be at risk
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
La Mesa, CaliforniaAges 6 months–5 years - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years - NCT04959734Recruiting
Study of COVID-19 effects on emergency visits for infant lung infections
This study looks at how the COVID-19 era changed emergency department visits for young children with breathing problems, such as bronchiolitis or first-time viral wheeze. It may help doctors understand trends in these illnesses and plan better care during outbreaks.
LeicesterAges birth–2 years - NCT05026749RecruitingPhase 3
Azithromycin for severe RSV breathing failure in young children
This trial tests whether azithromycin (an antibiotic) can improve outcomes for babies and young children in the ICU who have RSV causing serious breathing problems. It mainly looks at children who start strong breathing support soon after RSV symptoms begin.
Birmingham, AlabamaAges 3 days–2 years - NCT05045612RecruitingPhase 4
Antibiotics for certain viral lung infections in hospitalized adults
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
BergenAges 18 years+ - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT06521944Recruiting
RSV vaccine safety registry for pregnant people
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
Wilmington, North CarolinaAges 18–50 - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory syncytial virus (rsv)?
- Yes. Clin2 currently lists 37 recruiting respiratory syncytial virus (rsv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory syncytial virus (rsv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory syncytial virus (rsv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.